The First Sham-Controlled PCI Trial In Stable Patients
Executive Summary
More details about the controversial ORBITA trial.
You may also be interested in...
EuroPCR 2018: Several Studies Add Insight To Best Approach To Stable Coronary Disease, Utility Of FFR
New clinical data presented at the EuroPCR conference in Paris, including new data from ORBITA, suggest that fractional flow reserve/ instant wave-free ratio-guided percutaneous coronary intervention may produce better long-term outcomes than PCI guided by angiography in terms of mortality, restenosis and stent thrombosis.
ESC 2017: Renal-Denervation Redux? Medtronic Plans A New Pivotal Study Following Positive Data
Medtronic is re-upping its investments into renal denervation to treat hypertension after interim results were positive from a study testing the device procedure in patients not taking antihypertensive drugs. The firm announced it is launching a new pivotal study, more than three-and-a-half years after its last pivotal trial in the space failed.
Controversial laser heart procedures find little favour among US MCAC (Medicare coverage advisory committee) panel
There is too little evidence to judge the potential health benefits of a procedure that uses lasers to drill holes in the heart's myocardium following coronary artery bypass surgery, a panel of experts told Medicare last week.